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Renal ﬁbrosis is a hallmark of chronic kidney disease (CKD). It is generally thought
that transforming growth factor-b1 (TGF-b1) is a key mediator of ﬁbrosis and
mediates renal scarring positively by Smad2 and Smad3, but negatively by Smad7.
Our recent studies found that in CKD, TGF-b1 is not a sole molecule to activate
Smads. Many mediators such as angiotensin II and advanced glycation end
products can also activate Smads via both TGF-b-dependent and independent
mechanisms. In addition, Smads can interact with other signaling pathways, such
as the mitogen-activated protein kinase and nuclear factor-kappaB (NF-kB) path-
ways, to regulate renal inﬂammation and ﬁbrosis. In CKD, Smad2 and Smad3 are
highly activated, while Smad7 is reduced or lost. In the context of ﬁbrosis, Smad3 is
pathogenic and mediates renal ﬁbrosis by upregulating miR-21 and miR-192, but
down-regulating miR-29 and miR-200 families. By contrast, Smad2 and Smad7 are
protective. Overexpression of Smad7 inhibits both Smad3-mediated renal ﬁbrosis
and NF-kB-driven renal inﬂammation. Interestingly, Smad4 has diverse roles in
renal ﬁbrosis and inﬂammation. The complexity and distinct roles of individual
Smads in CKD suggest that treatment of CKD should aim to correct the imbalance
of Smad signaling or target the Smad3-dependent genes related to ﬁbrosis, rather
than to block the general effect of TGF-b1. Thus, treatment of CKD by overexpression
of Smad7 or targeting Smad3-dependent miRNAs such as downregulation of miR-21
or overexpression of miR-29 may represent novel therapeutic strategies for CKD.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Renal ﬁbrosis is a major pathologic feature of chronic
kidney disease (CKD) and is mediated by multiple media-
tors, including growth factors, cytokines, metabolic toxins,
and stress molecules via multiple mechanisms and
pathways. Among them, transforming growth factor-b1rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
ne and Therapeutics, and
nese University of Hong
ina.(TGF-b1) is a key mediator and has been shown to play a
pathogenic role in CKD [1–3].
TGF-b is a founding member of the TGF-b superfamily
that includes activins, inhibins, growth and differentiation
factors, and bone morphogenetic proteins. TGF-b1 is synthe-
sized by all cell types within the kidney. TGF-b1 is secreted
as latent precursors (latent TGF-b1) complexed with latent
TGF-b binding proteins (LTBP) [4]. TGF-b1 becomes active
when TGF-b1 is released from the latency-associated pep-
tide (LAP) and dissociated from LTBP via proteolytic cleavage
by plasmin, reactive oxygen species, thrombospondin-1, and
acid [4]. Active TGF-b then binds its receptors and functions
as autocrine and paracrine manners to exert its biologic andublished by Elsevier. This is an open access article under the CC BY-NC-
Figure 1. TGF-b/Smads and crosstalk pathways in renal ﬁbrosis and
inﬂammation. After binding to TbRII, TGF-b1 activates the TbRI-kinase,
which phosphorylates Smad2 and Smad3. The phosphorylated Smad2
and Smad3 then bind to Smad4 and form the Smad complex, which
translocates into the nucleus and regulates the target gene transcription,
including Smad7. Smad7 is an inhibitory Smad that functions to block
Smad2/3 activation by degrading the TbRI and Smads and to inhibit NF-
kB-driven inﬂammatory response by inducing IkBa, an inhibitor of NF-
kB. Note that Ang II and AGEs can activate Smads independent of TGF-b1
via the ERK/p38/MAPK crosstalk pathway. Red arrow lines (symbols)
indicate positive regulation and blue lines (symbols) indicate negative
regulation. AGE, advanced glycation end-products; Ang II, angiotensin II;
ERK, extracellular-signal-regulated kinases; IkBa, IkBa; MAPK, mitogen-
activated protein kinase; NF-kB, nuclear factor-kappaB; TGF-b, transform-
ing growth factor-b. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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and independent signaling pathways [5]. Of these pathways,
Smad signaling is a major mechanism by which TGF-b1
mediates CKD [2,3,6].
As shown in Fig. 1, after binding of TGF-b1 to its receptor
II (TbRII), TGF-b receptor type I (TbRI)-kinase becomes
phosphorylated, resulting in the activation of Smad2 and
Smad3, and two receptor-associated Smads (R-Smads) by
phosphorylation. The phosphorylated Smad2 and Smad3
then bind to the common Smad4 (Co-Smad) to form the
Smad complex, which translocates into the nucleus to
regulate the target gene transcription, including Smad7.
Smad7 is an inhibitory Smad (I-Smad) and speciﬁcally
binds E3 ligases (Smurfs and Arkadia) to negatively regulate
Smad2 and Smad3 activation and functions by targeting the
TbRI and Smads for degradation via the ubiquitin protea-
some degradation mechanisms [7,8].
In CKD, TGF-b/Smad signaling is deregulated, resulting in
overactivation of Smad2 and Smad3 but a loss of Smad7.
Thus, the imbalance of Smads may be a key mechanism
leading to renal scar formation and end-stage kidney disease.
In this paper, the current understanding of the distinct
role of individual Smads and the regulating mechanisms of
Smads and Smad-crosstalk pathways in renal ﬁbrosis andinﬂammation are introduced and the advances in treatment
of CKD by targeting the Smad pathway are described.Diverse roles of TGF-b1 in renal ﬁbrosis and
inﬂammation
It has been long recognized that TGF-b1 is a key
mediator in CKD [1–3]. TGF-b1 mediates progressive renal
ﬁbrosis by stimulating extracellular matrix (ECM) produc-
tion while inhibiting its degradation. In addition, TGF-b1
also induces the transformation of tubular epithelial cells
or endothelial cells to myoﬁbroblasts through epithelial-
mesenchymal transition (EMT) or endothelial-mesenchy-
mal transition (EndoMT) [9,10]. The functional role of TGF-
b1 in EMT and renal ﬁbrosis is demonstrated by the ability
of blocking TGF-b1 with neutralizing TGF-b antibodies,
decorin, and antisense oligonucleotides to prevent or
ameliorates renal ﬁbrosis in vivo and in vitro [3,11]. Direct
evidence for a role of TGF-b1 in renal ﬁbrosis comes from
studies that mice overexpressing an active form of TGF-b1
in liver develop progressive liver and renal ﬁbrosis [12,13].
Although the critical role of TGF-b1 in renal ﬁbrosis has
been well recognized, little attention has been paid to the
role of TGF-b1 in renal inﬂammation. TGF-b1 is also known
as an anti-inﬂammation cytokines [14]. Mice deﬁcient for
TGF-b1 results in the development of a lethal inﬂammation
and death at 3 weeks of age [15]. Similarly, conditional
deletion of TbRII or TGF-b1 gene from T cells develops
autoimmune diseases [16,17]. By contrast, mice overexpres-
sing human latent TGF-b1 are protected against progressive
renal inﬂammation and ﬁbrosis in obstructive and immu-
nologically induced crescentic glomerulonephritis [18–20].
Thus, TGF-b1 also plays a vital role in anti-inﬂammation.
Results from these studies implicate the complexity of TGF-
b1 in the pathogenesis of kidney disease and the necessity
to understand the diverse roles and mechanisms of active
versus latent TGF-b1 under disease conditions.Smad pathways in chronic kidney disease
In CKD, Smad2 and Smad3 are highly activated and
TGF-b is not a sole molecule to activate Smads [3,21]. As
shown in Fig. 1, many mediators including advanced
glycation end-products (AGE) and angiotensin II (Ang II)
can activate Smad2 and Smad3 and mediate renal ﬁbrosis
including connecting tissue growth factor (CTGF) expres-
sion via both TGF-b-dependent and independent mechan-
isms [22–25]. The later involves the mitogen-activated
protein kinase (MAPK)-Smad crosstalk pathway (Fig. 1).
This is supported by the ﬁndings that deletion of TGF-b1
or TGF-b receptor II is unable to prevent AGE-induced
Smad2 and Smad3 activation and ﬁbrosis [22,23]. By
contrast, blockade of the engagement of AGE to its
receptor (RAGE) with the soluble RAGE or ERK/p38 MAP
kinases with the speciﬁc inhibitors or dominant negative
adenovirus can prevent AGE-induced Smad2/3 activation
and renal ﬁbrosis [22,23], identifying the RAGE-ERK/p38
MAPK-Smad2/3 crosstalk pathway in the development of
diabetic complications. Similarly, under the hypertensive
Kidney Res Clin Pract 31 (2012) 4–116conditions, Ang II can activate Smad2/3 to stimulate ECM
production and EMT via the AT1-ERK/p38 MAPK-Smad2/3
crosstalk pathway in addition to the TGF-b-dependent
mechanism [24–26]. The important role for the MAPK-
Smad crosstalk pathway in AGE and Ang II-mediated renal
ﬁbrosis is further demonstrated by the ability of Ang II and
AGE to induce Smad3-mediated ﬁbrosis, including CTGF
expression and EMT in kidney cells lacking TGF-b1 gene or
TbRII, but not in those with a blockade of ERK/p38 MAP
kinases [23,25,26]. Therefore, in CKD, many mediators like
AGE and Ang II can bind to their own receptor and then
activate the Smad pathway via the TGF-b-independent
mechanism through the ERK/p38 MAPK pathway in addi-
tion to the TGF-b-dependent mechanism (Fig. 1). All of
these studies reveal the complexity of the activation of
Smads under disease conditions. These results may also
implicate that targeting the TGF-b signaling at the recep-
tor levels may not be an optimal therapeutic approach due
to the existing of the intracellular crosstalk pathways.Distinct roles of Smads in chronic kidney disease
Pathogenic role of Smad3 in renal ﬁbrosis
Smads have distinct roles in renal ﬁbrosis and inﬂam-
mation. In the context of renal ﬁbrosis, Smad2 and Smad3
are strongly activated in both experimental and human
kidney diseases, including diabetic nephropathy
[21–23,27–29], obstructive kidney diseases [30–33], rem-
nant kidney disease [26,34], drug-associated nephropathy
[35], and immunologically mediated glomerulonephritis
[20,36]. Many ﬁbrogenic genes, such as ColIa1, ColIa2,
ColIIIa1, ColVa2, ColVIa1, and ColVIa3 and the tissue
inhibitor of MMP-1 (TIMP-1), are the downstream targets
of TGF-b/Smad3 signaling [37] suggesting that Smad3 may
be a critical mediator of TGF-b/Smad signaling in ﬁbrosis.
An essential role for Smad3 in collagen matrix synthesis is
conﬁrmed by the ﬁndings that deletion of Smad3 from
mice suppresses ﬁbrosis in a number of rodent models,
including diabetic nephropathy [27] obstructive nephro-
pathy [30], and drug toxicity-related nephropathy [35].
Furthermore, the use of a Smad3 inhibitor to block TGF-
b1-induced endothelial-myoﬁbroblast transition in vitro
and renal ﬁbrosis in a type 1 diabetic kidney disease
demonstrates a therapeutic potential for kidney disease
by targeting Smad3 signaling [38].
Protective role of Smad2 in renal ﬁbrosis
By contrast to Smad3, our recent study demonstrated
that Smad2 is renoprotective in ﬁbrosis [39]. In condi-
tional Smad2 KO mice in which Smad2 is speciﬁcally
deleted from tubular epithelial cells by crossing the
Smad2 ﬂoxed mouse to the kidney speciﬁc promoter
(Cadherin 16)-driven Cre transgenic mouse [39]. Unex-
pectedly, we found that deletion of Smad2 from the
kidney signiﬁcantly enhances renal ﬁbrosis in a mouse
model of obstructive nephropathy. This may promote
Smad3 signaling, including Smad3 phosphorylation,
nuclear translocation, promoter activities, and the bindingof Smad3 to the collagen I promoter (COL1A2) [39]. Thus,
although it is commonly believed that Smad2 and Smad3
bind together physically and work in a nonredundant
manner in embryonic development, Smad2 may function
to competitively inhibit Smad3 activation and the subse-
quent binding to its target genes under pathophysiologic
conditions. Thus, the loss of Smad2 enhances Smad3-
mediated collagen matrix expression in response to TGF-
b1 and other ﬁbrotic mediators, including Ang II, AGE, and
nephrotoxin [23–26,35].
Differential role of Smad2 and Smad3 in EMT
Smad 2 and Smad3 also play a distinct role in EMT. Many
studies have demonstrated that Smad3 plays a critical role
in the EMT process in the kidney under various disease
conditions [26,30,35]. Our recent study found that disrup-
tion of Smad3 – but not Smad2 – attenuates Ang II-induced
EMT as identiﬁed by the loss of an epithelial marker
E-cadherin and the gain of mesenchymal phenotype
a-SMA [26]. This may be mediated by CTGF because the
knockdown of Smad3 – but not Smad2 – blocks AGE and
Ang II-induced CTGF expression and renal ﬁbrosis [23,26].
The ability of blocking Smad3 to inhibit EMT and EndoMT
in a variety of animal models conﬁrms a critical role for
Smad3 in the pathogenesis of CKD [10,38,40,41].Diverse role of Smad2 and Smad3 in angiogenesis
Smad2 and Smad3 also have a distinct role in angio-
genesis. Indeed, impaired angiogenesis leads to the pro-
gressive renal ﬁbrosis [42,43], whereas excessive
angiogenesis has been associated with the early develop-
ment of diabetic nephropathy [44]. It is now understood
that TGF-b acts by stimulating Smad2 and Smad3 to
control the process of angiogenesis by diversely regulating
expression of vascular endothelial growth factor (VEGF), a
proangiogenic factor, and thrombospondin-1 (TSP-1), an
antiangiogenic factor [45] Indeed, deletion of Smad3 – but
not Smad2 – is capable of blocking TGF-b1-induced VEGF
expression. Whereas, Smad2 – but not Smad3 – is critical
for TSP-1 expression [45]. These ﬁndings demonstrate a
critical role for Smad3 in angiogenesis while Smad2 is an
antiangiogenic factor in response to TGF-b1. Furthermore,
disruption of Smad2 – but not Smad3 – also inhibits TGF-
b1-induced expression of VEGF-A antagonist, a soluble
VEGF-A receptor sFlt-1, providing another evidence for a
role of Smad2 in antiangiogenesis [45]. It should be
pointed out that the differential regulating roles of Smad2
and Smad3 in angiogenesis under disease conditions are
complicated. For example, in the early development of
diabetic nephropathy, it is likely that the early activation
of TGF-b/Smad3 may induce VEGF to cause glomerular
hyperﬁltration, resulting in the development of albumi-
nuria. However, in the advanced diabetic nephropathy, it
is also highly possible that the prolonged activation of
Smad3 may stimulate renal ﬁbrosis, which – together with
Smad2 – may promote ischemic renal injury by impairing
the angiogenesis. Nevertheless, impaired angiogenesis has
Figure 2. Smad3-dependent miRNAs in renal ﬁbrosis. TGF-b1 acts by
stimulating Smad3 to positively regulate miR-21 and miR-192, but
negatively regulate the miR-29 or miR-200 families, to mediate renal
ﬁbrosis. Thus, overexpression of miR-29 or miR-200 or knockdown of
miR-21 and miR-192 may represent novel and speciﬁc therapeutic
strategies for renal ﬁbrosis. Red arrow lines (symbols) indicate positive
regulation and blue lines (symbols) indicate negative regulation. TGF-b,
transforming growth factor-b. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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ﬁbrosis in CKD [42,43].
Taken together, it can be concluded that Smad3, but not
Smad2, mediates renal ﬁbrosis. This new ﬁnding suggests
that treatment of renal ﬁbrosis should be speciﬁc by
targeting on Smad3, rather than Smad2. However, because
all of the results described above are from studies in vitro
and in a mouse model of obstructive nephropathy, it is
possible that Smad2 and Smad3 may function differently
in other disease conditions and in human CKD.
Distinct role of Smad4 in renal ﬁbrosis and inﬂammation
Although Smad4 is a common Smad in the signal
transduction pathway of the TGF-b family, a recent study
[46] found that Smad4 also plays a diverse role in renal
ﬁbrosis and inﬂammation. This is demonstrated by the
ﬁnding that conditional deletion of Smad4 from the
kidney enhances renal inﬂammation, including CD45þ
leukocyte and F4/80þ macrophage inﬁltration and upre-
gulation of proinﬂammatory cytokines, chemokine, and an
adhesion molecule in a mouse model of UUO nephropathy
[46]. By contrast, deletion of Smad4 inhibits progressive
renal ﬁbrosis. Although the exact mode of Smad4 in
kidney disease remains unclear, the diverse roles for
Smad4 in renal ﬁbrosis and inﬂammation suggest that
Smad4 may not be a therapeutic target for CKD.
Protective role of Smad7 in renal ﬁbrosis and inﬂammation
Smad7 is an inhibitory Smad and has a protective role
in renal ﬁbrosis and inﬂammation. Smad7 inhibits renal
ﬁbrosis by negatively regulating Smad2 and Smad3 acti-
vation via its negative feedback mechanism. Smad7 is
induced by TGF-b1 via the Smad3-dependent mechanism
[47–49]. By contrast, Smad7 inhibits Smad2 and Smad3
activation by causing the degradation of TbRI and Smads
via the ubiquitin–proteasome degradation mechanism
[7,8,49]. In CKD, TGF-b1 and Ang II are able to induce
Smad7 and E3 ligases (Smurfs and arkadia) mRNA expres-
sion; however, upregulation of the Smurfs and arkadia
degrades Smad7 protein via a post-transcriptional mod-
iﬁcation mechanism [7,8,26,49]. Indeed, Smurf1 and
Smurf2 as well as arkadia are E3 ubiquitin ligases for
Smad7 [7,8,50] and physically interact with Smad7
[50,51]. Smad7 acts as an adaptor protein to recruit
Smurf2 and arkadia to the TbRI to promote its degrada-
tion, including Smad7 itself [7,8,50,52]. Once Smad7 is
degraded, activation of Smad2/3 and renal ﬁbrosis is
enhanced. This is clearly demonstrated by the recent
ﬁnding that upregulation of renal Smurf2 causes an
ubiquitin-dependent degradation of renal Smad7, result-
ing in enhanced TGF-b/Smad signaling and progressive
renal ﬁbrosis [51]. Similarly, upregulation of renal Smurf2
also causes a degradation of Smad transcriptional co-
repressor SnoN, leading to progressive renal ﬁbrosis and
EMT in a mouse model of obstructive kidney disease [53].
Thus, degradation of Smad7 from the diseased kidney
promotes further Smad-dependent renal ﬁbrosis. This is
further supported by the ﬁndings that Smad7 KO micedevelop more severe renal ﬁbrosis in obstructive nephro-
pathy and diabetic kidney disease [29,33].
Smad7 exerts its inhibitory role in renal inﬂammation
by inducing IkBa expression, an inhibitor of nuclear
factor-kappaB (NF-kB), thereby preventing NF-kB from
activation (Fig. 1). In CKD, loss of renal Smad7 promotes
renal inﬂammation, which is associated with activation of
the NF-kB-dependent inﬂammatory pathway as evidenced
in crescentic glomerulonephritis, diabetic nephropathy,
and obstructive nephropathy [18,20,29,33,36]. In contrast,
overexpression of Smad7 substantially inhibits DNA bind-
ing activity, nuclear translocation, transcriptional activity
of NF-kB/p65, as well as NF-kB-dependent inﬂammatory
responses induced by IL-1b and tumor necrosis factor
alpha (TNF-a), which implicates a functional link between
the Smad7 and NF-kB [18]. Indeed, Smad7 is able to induce
IkBa expression, suggesting that TGF-b1 may act by
stimulating Smad7 to induce IkBa expression, thereby
inhibiting NF-kB activation and NF-kB-driven renal
inﬂammation [18]. The protective role of Smad7 in both
renal ﬁbrosis and inﬂammation strongly indicates that
Smad7 may be a therapeutic agent for CKD.Regulation of microRNAs by TGF-b/Smads during renal
ﬁbrosis
As shown in Fig. 2, recent studies showed that TGF-b
regulates speciﬁc microRNAs to mediate renal ﬁbrosis
Kidney Res Clin Pract 31 (2012) 4–118[21,54]. TGF-b1 upregulates miR-21, miR-93, miR-192,
miR-216a, miR-377, but downregulates the miR-29 and
miR-200 families [21,54]. We have recently identiﬁed that,
among these TGF-b-dependent miRNAs, miR-21, miR-192,
and the miR-29 family expression during renal ﬁbrosis is
tightly regulated by a TGF-b/Smad3 – but not Smad2 –
dependent mechanism because the deletion of Smad3 –
not Smad2 – inhibits the expression of miR-21 and miR-
192, but enhances the miR-29 family expression in
response to TGF-b1 [55–57]. Evidence supporting the
interaction of Smad3 with miR-21, miR-192, and miR-29
also came from the ﬁndings that there are conserved
Smad3-binding sites in the promoter region of all three
miRNAs and that Smad3 can interact with their individual
promoter region as detected by the ChiP assay [55–57].
The regulating role of TGF-b/Smad3 in miRNA expression
and renal ﬁbrosis is also detected in an experimental
mouse model of obstructive nephropathy by miRNA
microarray and real-time polymerase chain reaction
(PCR). Mice null for Smad3 are protected against renal
ﬁbrosis along with the inhibition of miR-21 and miR-192
expression [55,56]. By contrast, severe renal ﬁbrosis in the
obstructive nephropathy is associated with a loss of miR-
29, which is prevented in Smad3 knockout mice [57]. Of
interest, expression of miRNAs can also interact with
Smad3 to inﬂuence the Smad3 activity and functions. It
is reported that overexpression of miR-200a could
decrease Smad3 activity and attenuate TGF-b1-induced
ﬁbrosis [58].
Smad7 also plays a role in regulating Smad-dependent
miRNA expression in response to TGF-b1. For example, in
in vitro, overexpression of Smad7 in tubular epithelial cells
abolished TGF-b1-induced miR-192 expression [55]. In
in vivo, deletion of Smad7 enhanced Smad3 signaling,
thereby promoting miR-192 expression and ﬁbrosis in
obstructive kidney disease. By contrast, overexpression
of Smad7 blocks TGF-b/Smad signaling and thus inhibits
miR-192 expression and renal ﬁbrosis in the rat 5/6
nephrectomy model [55]. Again, results from the miRNA
studies support the pathogenic role for Smad3 – but not
Smad2 – and the protective role of Smad7 in renal ﬁbrosis.Smad7 as a therapeutic agent in CKD
Because of a diverse role for TGF-b1 in renal inﬂamma-
tion and ﬁbrosis, the blockade of the general effect of
TGF-b may not be an ideal therapeutic approach for CKD.
Thus, we proposed to target the downstream TGF-b
signaling pathway by exploring the therapeutic potential
of Smad7 [59]. As presented in Fig. 1, overexpression of
Smad7 not only inhibits activation of Smad2/3, but also
blocks NF-kB signaling by inducing IkBa. In CKD, renal
Smad7 is degraded along with overactivation of Smad3
and NF-kB signaling, which leads to progressive renal
ﬁbrosis and inﬂammation [3,59]. These ﬁndings suggest
that overexpression of Smad7 may be able to rebalance
the Smad and NF-kB pathways and therefore inhibits renal
ﬁbrosis and inﬂammation. Results from in vitro studies
support this hypothesis. Overexpression of Smad7 is ableto block TGF-b1, Ang II, and AGE-induced activation of
Smad2/3 and collagen matrix expression, including EMT
[22–26,60]. In addition, we also found that overexpression
of Smad7 is capable of inhibiting IL-1b-induced NF-kB
activation and inﬂammatory responses in vitro [18]. Find-
ings from in vitro studies provide strong rationale for
developing the therapeutic approach to prevent and treat-
ment CKD in vivo. To explore this therapeutic potential,
four studies have been performed. Using a virus-based
gene transfer technique, Smad7 is introduced into the
kidney followed by ligation of the left ureter to produce
obstructive nephropathy. Results show that overexpres-
sion of renal Smad7 can inhibit tubulointerstitial ﬁbrosis
[32]. Using an ultrasound-microbubble-mediated gene
transfer technique, we deliver a doxycycline-regulated
Smad7 gene into more than 90% the entire kidney cells,
thereby inhibiting progressive tubulointerstitial ﬁbrosis
after the left ureteral ligation [31]. Using this gene therapy
technique, we are also able to transfer the Smad7 gene into
the kidney, resulting in attenuating renal ﬁbrosis and
inﬂammation in a rat model of remnant kidney disease
[34,61], an immunologically induced crescentic glomeru-
lonephritis in mice [36,62], and diabetic nephropathy in
rats [29]. All of these studies clearly demonstrated that
ultrasound-mediated gene transfer of Smad7 can effec-
tively restore renal Smad7 to the normal levels under tight
control of doses of doxycycline in the drinking water. As
the resultant of overexpression of Smad7 in the diseased
kidney, the balance of intrarenal Smad and NF-kB signaling
pathways is achieved. Therefore, Smad3-mediated renal
ﬁbrosis and NF-kB-driven renal inﬂammation are inhibited
and renal functional impairment is prevented. All of these
studies demonstrate that Smad7 not only plays a nega-
tively regulating role in renal ﬁbrosis and inﬂammation,
but it also acts as a therapeutic agent and has therapeutic
effect on renal ﬁbrosis and inﬂammation [59].
However, it should be noted that because of the
counter-regulating role of Smad7 in a survival factor NF-
kB [63], uncontrollable overexpression of Smad7 could be
potentially harmful because higher levels of Smad7 can
also induce cell death through apoptosis in vivo and
in vitro [31,64–66]. Thus, it is critical to control the levels
of Smad7 to maintain a physiologic balance between the
TGF-b/Smad and NF-kB signaling pathways when
attempting to target TGF-b signaling with the overexpres-
sion of Smad7. This could be controlled using the doxycy-
cline-regulated Smad7 expressing system in which levels
of Smad7 within the cells or tissues is tightly controlled by
doses of doxycycline as reported in our extensive studies
in vivo and in vitro [59].Smad3-dependent miRNAs as therapeutic targets for
renal ﬁbrosis
Although TGF-b/Smad3 has been considered as a major
pathway for ﬁbrogenesis, the diverse roles of this pathway
in ﬁbrosis and immunity have hampered the development
of anti-TGF-b treatment in general. Indeed, mice lacking
either TGF-b1 or Smad3 have impaired immunity that
HY Lan / Smads as therapeutic targets for chronic kidney disease 9results in fatal inﬂammation in multiple organs or the
development of autoimmune disease [15,67]. Lessons
learned from the Smad3 knockout mice strongly indicate
that the development of therapeutic interventions for
renal ﬁbrosis involving this pathway should aim to speci-
ﬁcally target the TGF-b/Smad3-dependent genes that are
directly involved in ﬁbrogenesis rather than block the
general effect of the TGF-b/Smad3 signaling pathway.
The recent advances in miRNA research suggest that
targeting miRNAs may be an alterative strategy for treat-
ment of CKD. Indeed, several miRNAs, including miR-192,
miR-21, and miR-29, are speciﬁcally regulated by Smad3
and mediate renal ﬁbrosis in a Smad3-dependent manner
[54–58]. Thus, in the context of renal ﬁbrosis, we proposed
a novel therapeutic strategy by speciﬁcally targeting the
TGF-b/Smad3-dependent microRNAs that directly regulate
the ﬁbrosis genes (Fig. 2). The functional role of TGF-b/
Smad3-dependent miRNAs in renal ﬁbrosis is demon-
strated in vitro that overexpression of miR-21 and miR-
192 enhances – but knockdown of miR-21 or miR-192
inhibits – the collagen matrix expression in response to
TGF-b1 [55,56]. By contrast, knockdown of miR-29
enhances ﬁbrosis, whereas overexpression of miR-29
blocks collagen I expression in response to TGF-b1 [57].
Similarly, overexpression of miR-200a also downregulates
TGF-b1-induced EMT and extracellular matrix expression
in renal tubular epithelial cells [58].
More excitingly, we recently demonstrated that the
ultrasound-microbubble-mediated gene transfer techni-
que can also be used to deliver the miRNAs into the
kidney and have proved that the ultrasound-mediated
miRNA therapy is a novel and effective therapeutic
approach for kidney disease. Indeed, ultrasound-mediated
overexpression of miR-29b or knockdown of miR-21
before or after the established mouse model of obstructive
nephropathy is capable of preventing or halting the
progression of renal ﬁbrosis [56,57]. These ﬁndings sug-
gest that speciﬁc targeting the Smad3-dependent micro-
RNAs related to ﬁbrogenesis such as miR-21 and miR-29
may represent a novel and speciﬁc anti-ﬁbrosis therapy
for renal ﬁbrosis. However, it should be aware that the
regulating network of microRNAs is complicated. Different
genes can be regulated by a single miRNA, and a single
miRNA can regulate many different genes. It is also
possible that miRNAs can regulate each other in the
pathophysiologic processes via the co-regulatory mechan-
ism. Thus, the complexity within the regulatory network-
ing of TGF-b/Smads and miRNAs under pathologic
conditions should be considered when developing miRNA
as a potential therapeutic target for renal ﬁbrosis.Concluding remarks
The current understanding of the molecular mechan-
isms of TGF-b/Smads in renal ﬁbrosis and inﬂammation in
CKD has enabled us to develop speciﬁc therapeutic stra-
tegies for CKD. In general, Smad3 is a downstream key
mediator of TGF-b/Smad signaling and plays a pathogenic
role in renal ﬁbrosis by upregulating miR-21 and miR-192,but downregulating miR-29 and miR-200 families to
mediate renal ﬁbrosis (Fig. 2). By contrast, Smad2 is
renoprotective and suppresses renal ﬁbrosis by competi-
tively inhibiting Smad3 signaling. Smad4 is the common
Smad and plays a diverse role in promoting Smad3-
mediated renal ﬁbrosis but suppresses NF-kB-driven renal
inﬂammation by transcriptionally stimulating Smad7
expression. Most importantly, Smad7 is an inhibitor of
both Smad3-mediated renal ﬁbrosis and NF-kB-driven
renal inﬂammation. In CKD, TGF-b/Smad signaling is
imbalanced with highly activation of Smad2 and Smad3
but at a loss of Smad7. Therefore, therapies aimed to
restore the balance of both Smad and NF-kB signaling
pathways by overexpressing Smad7 or target Smad3-
dependent miRNAs related ﬁbrosis such as overexpression
of miR-29 while inhibiting miR-21 may represent novel
and effective therapeutic strategies for CKD.Conﬂict of interest
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